Common polymorphisms of growth hormone: Growth hormone receptor axis in Turkish children with short stature
View/ Open
Access
info:eu-repo/semantics/openAccessAttribution-NonCommercial 4.0 Internationalhttps://creativecommons.org/licenses/by-nc/4.0/Date
2022Author
Yılmaz Güleç, ElifErcan, Oya
Adal, Servet Erdal
Buyru, Ayşe Nur
Yıldız, Metin
Deviren, Ayhan
Metadata
Show full item recordCitation
Yılmaz G. E., Ercan, O., Adal, S. E., Buyru, A. N., Yıldız, M. ve Deviren, A. (2022). Common polymorphisms of growth hormone: Growth hormone receptor axis in Turkish children with short stature. Turkish Archives of Pediatrics, 57(2), 160-167. https://doi.org/10.5152/TurkArchPediatr.2022.21129Abstract
Objective: A single-nucleotide polymorphism of the growth hormone 1 gene, GH1IVS4+90A>T (rs2665802), associated with short stature and a polymorphism of the growth hormone receptor gene, exon 3 deleted variant, associated with increased responsiveness to growth hormone have been reported previously. We aimed to investigate the frequency of both polymorphisms and their correlation to height in Turkish short children. Also, we aimed to evaluate the effect of exon 3 deleted variant on response to 1-year growth hormone therapy. Materials and Methods: Children with idiopathic isolated growth hormone deficiency (n = 39) and with idiopathic short stature (n = 10) and 50 control subjects were evaluated for anthropo-metric parameters, annual growth velocity, and annual height gain. Growth hormone receptor gene polymorphisms were analyzed via multiplex polymerase chain reaction; growth hormone 1 gene polymorphism was analyzed via polymerase chain reaction and single-strand confor-mation polymorphism techniques. Results: The frequency of genotypes carrying the “A” allele was not significantly higher in the idiopathic isolated growth hormone deficiency group than in the idiopathic short stature and control groups (P = .03 for each). The exon 3 deleted variant genotype was significantly lower in the idiopathic short stature group compared to the control group (P = .01). There was no effect of exon 3 deleted variant, on response to the first-year growth hormone therapy. Conclusion: In Turkish population, no correlation was found between the “A” allele of GH1IVS4+90A>T polymorphism and idiopathic isolated growth hormone deficiency and short stature, and a significant negative correlation was found between exon 3 deleted variant and idiopathic short stature and short stature. Exon 3 deleted variant has no effect on response to growth hormone treatment.
Source
Turkish Archives of PediatricsVolume
57Issue
2Collections
Related items
Showing items related by title, author, creator and subject.
-
Response to growth hormone treatment in very young patients with growth hormone deficiencies and mini-puberty
Çetinkaya, Semra; Poyrazoğlu, Şükran; Baş, Firdevs; Ercan, Oya; Yıldız, Metin; Adal, Erdal; Bereket, Abdullah; Abalı, Saygın; Aycan, Zehra; Erdeve, Senay Savaş; Berberoğlu, Merih; Şıklar, Zeynep; Tayfun, Meltem; Darcan, Şükran; Mengen, Eda; Bircan, İffet; Jones, Filiz Mine Çizmecioğlu; Şimşek, Enver; Papatya, Esra Deniz; Özbek, Mehmet Nuri; Bolu, Semih; Abacı, Ayhan; Büyükinan, Muammer; Darendeliler, Feyza (Walter de Gruyter Gmbh, 2018)Background: The aim of the study was to assess the response to growth hormone (GH) treatment in very young patients with GH deficiency (GHD) through a national, multi-center study. Possible factors affecting growth response ... -
Gut microbiota in patients with newly diagnosed acromegaly: A pilot cross-sectional study
Hacıoğlu, Ayşa; Gündoğdu, Aycan; Nalbantoğlu, Ufuk; Karaca, Züleyha; Urhan, Muhammed Emre; Şahin, Serdar; Dökmetaş, Hatice Sebile; Kadıoğlu, Pınar; Keleştimur, Fahrettin (Springer, 2021)Purpose Microbiota has crucial biological importance for human well-being. Bidirectional interaction exists between microbiota and the host, and there have been no studies investigating this interaction in patients with ... -
Hedonik obezitenin sinir bilimsel kökenleri
Dilsiz, Pelin (İstanbul Medipol Üniversitesi Sağlık Bilimleri Enstitüsü, 2017)Dünyada 600 milyondan fazla insanda görülen obezite, beraberinde mortalite riski yüksek birçok hastalığı da tetikleyen global bir sağlık sorunudur. Mevcut tedavi yöntemlerinin yetersiz kalması, obezite tedavisinde yeni ...